Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Timothy P. Hughes(Royal Adelaide Hospital), Susan Branford(South Australia Pathology), Christopher Arthur(Royal North Shore Hospital), Deborah L. White(ANZCHOG), Naranie Shanmuganathan(South Australia Pathology), David M. Ross(Flinders Medical Centre), Jodi Braley(South Australia Pathology), Anthony K. Mills(Princess Alexandra Hospital), Chung Hoow Kok(South Australian Health and Medical Research Institute), John F. Seymour(The Royal Melbourne Hospital), Verity A Saunders(South Australia Pathology), Ilaria S. Pagani(South Australian Health and Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Andrew Grigg(The Royal Melbourne Hospital), Anthony P. Schwarer(The Alfred Hospital), Robin Filshie(St Vincent's Hospital Melbourne), David T Yeung(Royal Adelaide Hospital), Phuong Dang(South Australia Pathology)
Cited by 78
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k